Fine Needle Aspiration Biopsy of Palpable Breast Masses Is Associated with Shorter Length of Time to First Treatment Compared with Core Biopsy
Amy Ly, Jill Ono, Kevin Hughes, Martha B Pitman, Ronald Balassanian. Brigham and Women's Hospital, Boston, MA; Massachusetts General Hospital, Boston, MA; University of California, San Francisco, CA
Background: Time to treatment has been shown to be an important measure of quality in cancer care. Fine Needle Aspiration Biopsy (FNAB) for the evaluation of breast lesions remains underutilized and has been supplanted by core biopsy (CB) in many centers. We compared time to treatment in two matched patient cohorts with palpable breast masses diagnosed by either FNAB or CB.
Design: We reviewed medical records of all patients who received FNAB or CB in 2009 for palpable breast masses at two affiliated tertiary academic medical centers. One center utilized a pathologist-run FNAB clinic and the other utilized CB almost exclusively. Data retrieved from the common lab information system included age, lesion size (by palpation for FNAB, by imaging for CB), diagnosis, and time from presentation to excision or neoadjuvant therapy (NEO).
Results: Of 257 total FNAB, 51 went to excision and 3 received NEO (mean age 52; range 19-92). Of 1346 total CB, 103 were excised and 15 were treated with NEO (mean age 52; range 18-87). At time of biopsy, median breast mass size for FNAB was 1.5 cm (range 0.4-7.0) and for CB was 1.7 cm (range 0.3-6.0). Median carcinoma size for FNAB was 1.8 cm (mean 2.09, range 0.9-3.1) and for CB was 2.1 cm (mean 2.35, range 0.4-8.0). Median time from presentation to excision or NEO was shorter for FNAB patients.
|All Patients||All Patients||All Patients||Benign Lesions||Benign Lesions||Benign Lesions|
|Indeterminate Lesions||Indeterminate Lesions||Indeterminate Lesions||Malignant Lesions||Malignant Lesions||Malignant Lesions|